Fischer and Lewis rat strains differ in basal levels of neurofilament proteins and their regulation by chronic morphine in the mesolimbic dopamine system.
We studied levels of neurofilament (NF) proteins in the ventral tegmental area (VTA), and other regions of the central nervous system, of two genetically inbred rat strains, Lewis (LEW) and Fischer (F344) rats. These strains represent genetically divergent populations of rats that have been used to study possible genetic factors involved in a variety of biological processes, including drug addiction: compared to F344 rats, LEW rats show a much higher preference for several classes of drugs of abuse. We found 30-50% lower levels of three NF proteins, NF-200 (NF-H), NF-160 (NF-M), and NF-68 (NF-L), in the VTA of LEW compared to F344 rats by use of immunolabeling and Coomassie blue staining. These strain differences were highly specific to this brain region, with no differences observed elsewhere in brain or spinal cord. Interestingly, chronic treatment of F344 rats with morphine decreased levels of these three NF proteins in the VTA, as found previously in outbred Sprague-Dawley rats (Beitner-Johnson, D., Guitart, X., and Nestler, E.J.:J. Neurosci., 12:2165-2176, 1992), whereas morphine had no effect on NF levels in the VTA of LEW rats. A similar strain difference was observed in chronic morphine regulation of tyrosine hydroxylase, with morphine increasing enzyme immunoreactivity in the VTA of F344 rats (as has been observed previously in Sprague-Dawley rats [Beitner-Johnson, D., and Nestler, E.J.:J. Neurochem., 57:344-347, 1991]), but not in LEW rats. In view of the observations that LEW and F344 rats show different levels of preference for several types of drugs of abuse, and of the evidence supporting a central role of the mesolimbic dopamine system in drug reward mechanisms, the results of the current study suggest the possibility that levels of NFs and tyrosine hydroxylase may mediate some aspects of drug reinforcement and contribute to individual genetic differences in vulnerability to drug addiction.
Guitart
X
X
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.
Beitner-Johnson
D
D
Marby
D W
DW
Kosten
T A
TA
Nestler
E J
EJ
D000818:Animals; D001921:Brain / Q000378:metabolism; D003042:Cocaine / Q000008:administration & dosage; D003598:Cytoskeletal Proteins / Q000378:metabolism; D004298:Dopamine / Q000502:physiology*; D008032:Limbic System / Q000378:metabolism / Q000502:physiology*; D008297:Male; D009020:Morphine / Q000008:administration & dosage / Q000494:pharmacology*; D016900:Neurofilament Proteins / Q000378:metabolism*; D051381:Rats; D011916:Rats, Inbred F344 / Q000378:metabolism / Q000502:physiology*; D011917:Rats, Inbred Lew / Q000378:metabolism / Q000502:physiology*; D012646:Self Administration; D013681:Tegmentum Mesencephali / Q000378:metabolism; D013997:Time Factors; D014018:Tissue Distribution; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D003598:Cytoskeletal Proteins; D016900:Neurofilament Proteins; D009020:Morphine; D014446:Tyrosine 3-Monooxygenase; D003042:Cocaine; D004298:Dopamine